Abstract: The present disclosure is directed to methods of treating and preventing colorectal cancer metastasis or recurrence of colorectal cancer with compositions comprising anti-progastrin antibodies.
Type:
Application
Filed:
January 4, 2011
Publication date:
July 21, 2011
Applicants:
BIOREALITES, S.A.S., INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.
Type:
Application
Filed:
October 15, 2010
Publication date:
May 19, 2011
Applicants:
BIORÉALITÉS S.A.S., INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)